Christoph A, et al. – The first phase II, randomized, double–blind, placebo– and the active–controlled trial was performed to assess the analgesic efficacy, safety, and tolerability of cebranopadol in patients with moderate–to–severe chronic low back pain (LBP) with and without neuropathic pain component. The researchers concluded that cebranopadol was found to be a new drug candidate with a novel mechanistic approach for potential chronic LBP treatment. However, further optimizing the titration scheme to the optimal dose for individual patients was essential.